Stanford Cancer Institute

Stanford MEDICINE

Stanford Cancer Institute

Various/Other

Version Date:
February 25, 2022.

Solid Tumors

Treatment

HER2+

VAR0161
Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

PI: Wakelee
Seattle Genetics, Inc.

VAR0200
Phase I/II Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors

PI: Pegram
Bolt Biotherapeutics, Inc.

MATCH Screening

If matches (a) mutation(s) in 1 ≤ treatment arms

ECOG-ACRIN-EAY131 ❖
Molecular Analysis for Therapy Choice (MATCH)

PI: Ford
ECOG-ACRIN

LUNG SABR

BONE0012
MR guided Focused Ultrasound versus Radiotherapy for Palliative Pain Treatment in Patients with Bone Metastases

PI: Ghanouni
Stanford

LUN0124
Phase I Evaluate Percussive Ventilation Breathhold to Improve Lung StereotacticAblative Radiotherapy

PI: Blomain
Stanford

GI0023
Phase I/II ELI-002 ImmunoTx in KirstenRat Sarcoma MutatedPancreatic Ductal Adenocarcinoma &SolidTumors

PI: Fisher
Stanford

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- ❖ Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu